Unibest proudly partners with a renowned supplier to bring you Semagcare, a premium product line featuring in-housed developed Semaglutide API and Semaglutide tablets available in 3mg, 7mg, and 14mg dosages.

Key Features

• Semagcare: High-quality Semaglutide tablets intended for diabetes, obesity treatment and potential cardiovascular benefits ready for distributor collaboration.

• GMP: Manufactured in facilities with complete GMP qualifications to ensure the highest standards of quality and safety.

• Dossier: Currently, clinical trials are in progress, and global DMF is expected to be obtained by the end of December 2024. The supplier can assist in dossier submission based on the specific requirements of different countries' health authorities.

• API Sourcing: High quality in-house developed Semaglutide API and intermediates, produced through advanced fermentation and chemical synthesis.

• Market Experience: Successful market experience in Southeast Asia with millions of tablets sold in 8 months.
  

About Our Supplier

Our supplier is a subsidiary of a NASDAQ-listed pharmaceutical giant, specializing in the R&D and sales of biologics and innovative drugs. With an impressive setup of 200 R&D staff and 13,000 square meters of cutting-edge labs, they cover various fields including fermentation, peptide synthesis, and enzyme catalysis. The production arm is equally commendable, featuring 200,000 square meters of facilities and a workforce of 700 employees in mainland China.

Feeding Preparation and Filtration

Fermentation System

Centrifugation and Homogenization

Granulation, Pelleting, and Analysis

Regulatory Status

Semaglutide (Ozempic and Wegovy), originally developed by Novo Nordisk, is protected by 33 effective patents. Laos, as an LDC under WTO, enjoys IP waivers allowing legal production and sale of generics until 2033 under TRIPS and Doha Declaration on TRIPS and Public Health. Our partner's investment in a production site in Laos gives them a strategic advantage, allowing them to produce Semaglutide API and submit a global DMF by the second half of 2024.

Laos Semaglutide Manufacturing Site

Certifications & Documentation

The supplier holds a formal drug registration certificate in Southeast Asia, backed by a rigorous GMP qualification process at the manufacturing facility. Currently, the supplier is in the process of clinical trials to assess the BE.

BE - Semagcare and Semglutide Dissolution Test

Ideal For

• Distributors looking for a reliable source of high-quality Semaglutide tablets.

• FDF Manufacturers aiming to develop Semaglutide Finished Dosage Forms (FDF). With our partnership, you get access to Semaglutide API and a one-stop solution for FDF development.

Why Partner with Unibest

Our vision at Unibest is to be the best partner for global pharmaceutical companies. By leveraging advanced technologies and environmentally friendly practices, we provide sustainable solutions throughout the drug life cycle. Explore our portfolio of high-value pharmaceutical intermediates and APIs, and let us help you maximize market value.

Unibest has compiled a list of Semaglutide development 'checklist' to tailor to your specific needs: 

- If you are interested in becoming a distributor of Semaglutide tables, take your distribution and FDF development to the next level with Semagcare from Unibest;

- If you want to develop injection other than tablets, Unibest is ready to supply Semaglutide API;

- If you have a strong synthesis capabilities, and want to develop Semaglutide from Semaglutide intermediates, check out our Semaglutide pipeline.

For more information, use this link to send your inqury.